Thymoquinone (TQ) in Oncology – Deep Dive
Learn how TQ works on different aspects of cancer, from stopping cancer cell growth and spread, to triggering cancer cell death, reducing inflammation, and helping the immune system fight back.
Thymoquinone (TQ), the active compound in Nigella sativa (black seed), has shown promising effects against cancer in many laboratory studies. In this deep dive, we explore how TQ works on different aspects of cancer, from stopping cancer cell growth and spread, to triggering cancer cell death, reducing inflammation, and helping the immune system fight back.
We also highlight how TQ may overcome one of the biggest problems in cancer treatment—chemo-resistance. When used together with common treatments like chemotherapy, radiation, or immunotherapy, TQ has been shown to improve their effects and reduce harmful side effects in preclinical models.
Learn how TQ affects cancer stem cells, the tumor environment, and gene regulation through epigenetics. Through this deep dive, we unpack the wide-ranging potential of TQ as a natural compound that may help make cancer treatments more effective and better tolerated. We call for clinical studies to take this research further and bring TQ closer to use in real-world cancer care.
TQ deep dive jump menu
Thymoquinone and cancer: what the research does—and does not—show
Mechanisms: plausible biology, not established patient benefit
Thymoquinone and cancer: what the research does—and does not—show
Thymoquinone (TQ) is a small quinone found in the volatile oil of Nigella sativa (black seed/black cumin). Cancer research on purified TQ is extensive at the cell-culture level and includes multiple animal tumor models. It repeatedly shows biological activity—often slowing cancer-cell growth, inducing cell death, and changing pathways linked to survival, inflammation, invasion, or drug resistance.
Presently (2026), the research is not at the stage of saying that taking black seed oil or TQ treats cancer in people. Clinical evidence is still sparse, formulations differ, human exposure is not well characterised, and no dependable oncology dose or timing has been established.
TQ should not replace, delay, or be added to cancer treatment without the oncology team's review.
Evidence at a glance 2026: strongest for laboratory mechanisms; promising but inconsistent preclinical combination results; very limited human cancer evidence.
Be sure to read the page unpacking why natural medicines often lack large clinical trials
How the evidence was gathered—and its limits
I searched PubMed, Semantic Scholar, and OpenAlex on 13 October 2026 for TQ/Nigella sativa and oncology, cancer-type studies, mechanisms including redox/NRF2/ferroptosis, human dosing/safety/pharmacokinetics, drug interactions, immune effects, antimicrobial/anti-fungal activity, and formulation quality.
I prioritised primary experiments for specific findings and reviews for broad patterns.
Evidence by cancer type
Most tumor-specific evidence remains preclinical. The examples below are illustrative, not a ranking of proven treatments.
Cancer/model | What was reported | How to read it |
|---|---|---|
Breast | In a breast xenograft mouse model, TQ increased tumor-cell oxidative stress and apoptosis; doxorubicin strengthened tumor suppression [2]. TQ also sensitised cell and animal models to gemcitabine [3]. | Cell and mouse evidence, not clinical proof. Combination effects vary by drug and model. |
Pancreatic | In an orthotopic mouse model and cell experiments, pretreatment with TQ followed by gemcitabine or oxaliplatin improved tumor inhibition and reduced NF-κB-associated survival signaling [4]. | One of the more developed model areas, but still experimental and dosing cannot be transferred to patients. |
Colorectal | In mouse models of chemically induced and transplanted colon tumors, TQ reduced aberrant crypt foci and tumor burden; other studies report p53-linked apoptosis in colon-cancer cells [5], [6]. | Animal and cell outcomes; no basis to use TQ for prevention or treatment in people. |
Lung | A mouse xenograft study reported lower lung-tumor growth with TQ plus cisplatin than control, while 2025 work on non-small-cell lung cancer mainly reports cell-model effects with cisplatin/radiation [7], [8]. | Some animal support for a combination, but no clinical validation. |
Blood cancers | Leukemia-cell and primary-cell experiments linked TQ to reduced DNA methylation and apoptosis, and leukemia-bearing mice showed regression [9]. | Early translational evidence; primary patient cells tested outside the body are not patient treatment outcomes. |
Kidney, liver, ovarian, and other tumors | Kidney-cancer studies report ROS-related cell death and, in 2025, a proposed ferroptosis pathway [10], [11]. Liver-cancer cells showed synergy with doxorubicin/cisplatin [12]. An ovarian-cancer mouse study found benefit with cisplatin but also a warning signal: TQ alone increased ascites and tumor NF-κB activity [13]. | Effects differ by model and tumor environment; the ovarian finding shows why “natural” does not mean uniformly beneficial or safe. |
Across cancer types, the pattern is therefore a broad preclinical signal, not a consistent clinical effect. Sensitivity depends on cell type, dose, treatment combination, and biological context; even high-profile combination claims are primarily based on cells or animals [14], [15].
Mechanisms: plausible biology, not established patient benefit
Cell death and growth arrest. Common experimental findings include mitochondrial apoptosis, caspase activation, shifts in pro-/anti-apoptotic proteins (such as Bax and Bcl-2), and cell-cycle arrest. TQ also changes multiple signaling networks—often PI3K/Akt, NF-κB, STAT3, p53, MAPK, and PTEN—rather than acting like a single-target drug [14], [16]. The specific pathway is not consistent across tumors: for example, colon-cell experiments support a p53-dependent response, whereas hepatocellular-cancer models found greater TQ sensitivity after p53 loss [6], [12]. These results argue against assuming one mechanism or a uniform responder group.
Redox: antioxidant and pro-oxidant effects can coexist. TQ can scavenge radicals or raise antioxidant defenses in some settings, but in several cancer models its cytotoxic effects depend on increased reactive oxygen species (ROS) and oxidative damage. Blocking ROS with an antioxidant prevented some TQ-induced cancer-cell death in kidney and liver models [10], [17]. In triple-negative breast-cancer cells, by contrast, TQ increased NRF2 and antioxidant-defence markers while lowering measured PD-L1 protein [18]. NRF2 is a context-dependent stress-response pathway, not a simple “good” or “bad” marker; an increase in a cell experiment does not predict benefit in a person. Thus, TQ should not be casually combined with antioxidant supplements during cancer therapy: the direction and clinical importance of any interaction are unknown.
NRF2 and ferroptosis. The NRF2 result above is cell-line evidence. A 2025 renal-cancer study additionally proposed ferroptosis—iron-associated lipid damage and cell death—after TQ reduced SERPINH1 and altered ROS, glutathione, and iron measures [11]. This is a recent, early mechanism in a narrow model; it does not establish ferroptosis as a general TQ mechanism or a patient treatment strategy.
Resistance, stem-like cells, and combinations. Researchers have tested TQ with chemotherapy and radiation as a sensitiser, with possible effects on drug-efflux proteins, survival pathways, or stem-like cancer-cell populations. However, “synergy” is not universal: one breast-cancer experiment found synergy with gemcitabine but antagonism with paclitaxel under tested conditions [3], [19]. A lab combination index is not evidence that a supplement improves a patient's response. Do not infer that TQ will protect normal organs or make treatment safer in people; those claims largely arise from preclinical models and could vary with the specific drug and schedule [1], [15].
Immune-oncology relevance
Several signals are interesting but preliminary. In human blood immune cells grown outside the body, low-dose TQ increased T-cell activation/proliferation and the treated cells showed greater tumor-cell killing in co-culture; higher concentrations also increased T-cell death [20]. A 2025 mouse cervical-cancer vaccine model reported more CD4/CD8 T-cell infiltration, fewer regulatory T cells, and stronger vaccine-associated tumor control with TQ [21]. These findings support further study, not use with checkpoint inhibitors or therapeutic vaccines. One small renal-cancer model reported improved response with nivolumab, but it was experimental and cannot establish clinical compatibility [22]. TQ's immunologic effects may depend on concentration, timing, and the surrounding immune environment.
Human evidence, safety, dose, and timing
What has been studied in people? One report describes 80 breast-cancer patients divided among tamoxifen, TQ, their combination, and untreated-control groups; its abstract reports five-year survival and relapse differences, but does not provide numerical outcome estimates, TQ formulation/dose, or enough detail to assess allocation or attrition [23]. A 2025 randomised study enrolled 48 people with oral leukoplakia, a precancerous condition, and tested local Nigella sativa extract tablets for three months; it reported smaller lesions and biomarker changes, but this was a plant extract and prevention/lesion study, not treatment of invasive cancer with purified TQ [24].
Safety and interactions. Animal studies often report tolerability at selected doses, but animal safety cannot define safety in people receiving chemotherapy, radiation, surgery, immunotherapy, or multiple medicines. Human dosing and long-term safety for purified TQ in cancer care remain undetermined. Laboratory studies indicate that TQ can inhibit CYP3A4 and CYP2C19, enzymes involved in handling many medicines [25]. In human liver microsomes/cells, it also changed warfarin metabolism; this was not a patient interaction trial, but it raises a reason for caution with warfarin [26]. In rats, TQ changed 5-fluorouracil exposure (higher peak concentration and overall exposure) [27], and another rodent study suggested reduced oral cyclosporine bioavailability [28]. These are not enough to predict a clinical effect, but they make unsupervised use particularly unwise during cancer treatment or when taking anticoagulants, transplant medicines, seizure medicines, or drugs with narrow therapeutic ranges.
Dosing and timing. There is no validated anticancer dose, route, or schedule for people. Experimental doses vary greatly and are often delivered to cells directly or injected into animals; these cannot be converted into a safe/effective supplement regimen. An animal study found a plasma half-life of about 2.3 hours after intraperitoneal dosing in mice, but this does not tell us how oral black seed oil behaves in patients [29]. Research has tested pretreatment before chemotherapy in models, but no clinical evidence establishes whether TQ should be taken before, during, or after a cancer treatment. Patients should tell their oncology pharmacist and physician the exact product, dose, and schedule before using it.
Product sourcing and formulation quality
“Black seed oil,” seed powder, a Nigella sativa extract, and purified TQ are not interchangeable. They contain different mixtures and can have very different TQ concentrations. In one analysis of six oils and five capsules, measured TQ content ranged from 3.08 to 809.4 mg per 100 g [30]. That wide range means the product name or front-label amount alone may not reveal the delivered TQ dose.
For research or clinical use, the important quality features are batch-specific TQ assay (for example, HPLC), identity and purity, clear distinction between oil/extract and purified TQ, contaminant testing, stability/storage information, and reliable manufacturing documentation. Ask for a certificate of analysis; avoid products that claim to cure cancer or do not specify what they contain.
Our community's Trusted Supplier and discounts page includes a link to learn more about pure Egyptian cold pressed Black Cumin Seed Oil softgels.
Antimicrobial and antifungal relevance
TQ has laboratory activity against bacteria and fungi, and recent experiments describe inhibition of Candida biofilm formation or synergy with nystatin in vitro [33], [34]. A study of clinical Candida glabrata isolates from intensive-care patients also reported anti-fungal/anti-biofilm effects in vitro [35].
This could motivate research into oral candidiasis or other infections, but it is not firm evidence yet that oral TQ or black seed oil prevents or treats fungal infection in cancer patients.
Practical take-home
TQ is a biologically active research compound with substantial preclinical anticancer findings.
References
[1] N. Al-Damook, M. Sakkal, M. Khair, W. Mousa, G. Khoder, and R. Ghemrawi, “Targeting cancer through thymoquinone: From molecular mechanisms to clinical prospects,” International Journal of Molecular Sciences, 2025, doi: 10.3390/ijms262211029.
[2] C. C. Woo, A. Hsu, A. Kumar, G. Sethi, and K. H. Tan, “Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: The role of p38 MAPK and ROS,” PLoS ONE, 2013, doi: 10.1371/journal.pone.0075356.
[3] H. A. Bashmail et al., “Thymoquinone synergizes gemcitabine anti-breast cancer activity via modulating its apoptotic and autophagic activities,” Scientific reports, 2018, doi: 10.1038/s41598-018-30046-z.
[4] S. Banerjee et al., “Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer.” Cancer Research, 2009, doi: 10.1158/0008-5472.CAN-08-4235.
[5] H. Gali-Muhtasib et al., “Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models,” Journal of cellular and molecular medicine, 2008, doi: 10.1111/j.1582-4934.2007.00095.x.
[6] H. Gali-Muhtasib et al., “Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism.” International Journal of Oncology, 2004, doi: 10.3892/IJO.25.4.857.
[7] S. H. R. Jafri, J. Glass, R. Shi, S. Zhang, M. Prince, and H. E. Kleiner-Hancock, “Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo,” Journal of Experimental & Clinical Cancer Research, 2010, doi: 10.1186/1756-9966-29-87.
[8] M. Gurbilek et al., “Anticancer activity of thymoquinone in non-small cell lung cancer and possible involvement of PPAR-γ pathway,” International Journal of Radiation Biology, 2025, doi: 10.1080/09553002.2025.2449953.
[9] J. Pang et al., “Thymoquinone exerts potent growth-suppressive activity on leukemia through DNA hypermethylation reversal in leukemia cells,” Oncotarget, 2017, doi: 10.18632/oncotarget.16431.
[10] I. G. Chae, N.-Y. Song, D.-H. Kim, M.-Y. Lee, J.-M. Park, and K.-S. Chun, “Thymoquinone induces apoptosis of human renal carcinoma caki-1 cells by inhibiting JAK2/STAT3 through pro-oxidant effect,” Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2020, doi: 10.1016/j.fct.2020.111253.
[11] R. Luo, S. Li, H. Wang, Z. Zhang, L. Li, and P. Shang, “Thymoquinone suppresses cell growth and induces ferroptosis in renal cell carcinoma by reducing SERPINH1 expression,” Letters in Drug Design & Discovery, 2025, doi: 10.1016/j.lddd.2025.100013.
[12] S. Jehan, Z. Chen, G. Li, S. Z. Bakhtiar, D. Li, and G. Sui, “Thymoquinone selectively induces hepatocellular carcinoma cell apoptosis in synergism with clinical therapeutics and dependence of p53 status,” Frontiers in Pharmacology, vol. 11, p. 555283, 2020, doi: 10.3389/fphar.2020.555283.
[13] A. J. Wilson, J. Saskowski, W. Barham, F. Yull, and D. Khabele, “Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer,” Journal of ovarian research, 2015, doi: 10.1186/s13048-015-0177-8.
[14] A. F. Majdalawieh, M. W. Fayyad, and G. K. Nasrallah, “Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of nigella sativa,” Critical Reviews in Food Science and Nutrition, 2017, doi: 10.1080/10408398.2016.1277971.
[15] S. Jehan, J. Huang, U. Farooq, I. Basheer, and W. Zhou, “Combinatorial effect of thymoquinone with chemo agents for tumor therapy,” Phytomedicine : international journal of phytotherapy and phytopharmacology, 2022, doi: 10.1016/j.phymed.2022.153936.
[16] E. Sadeghi, M. Imenshahidi, and H. Hosseinzadeh, “Molecular mechanisms and signaling pathways of black cumin (nigella sativa) and its active constituent, thymoquinone: A review,” Molecular Biology Reports, 2023, doi: 10.1007/s11033-023-08363-y.
[17] A. E. Ashour et al., “Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis,” Molecular and cellular biochemistry, 2014, doi: 10.1007/s11010-013-1930-1.
[18] G. M. Adinew, S. Messeha, E. Taka, R. Badisa, and K. Soliman, “Anticancer effects of thymoquinone through the antioxidant activity, upregulation of Nrf2, and downregulation of PD-L1 in triple-negative breast cancer cells,” Nutrients, 2022, doi: 10.3390/nu14224787.
[19] H. A. Bashmail, A. A. Alamoudi, G. A. Hegazy, G. M. A. Agabnoor, A. Noorwali, and A. M. Al-Abd, “Abstract 2995: Thymoquinone attenuates breast cancer cell resistance to paclitaxel via targeting tumor associated stem cell population,” Cancer Research, 2019, doi: 10.1158/1538-7445.am2019-2995.
[20] R. Pandey, C. Sirbu, G. R. Hankins, T. E. Fandy, and W. Du, “Thymoquinone treatment enhances t cell-mediated anti-tumor response,” The Journal of Immunology, 2023, doi: 10.4049/jimmunol.210.supp.172.05.
[21] Y. Che et al., “Thymoquinone enhances efficacy of cervical cancer therapeutic vaccines via modulating CD8+ t cells.” International Immunopharmacology, 2025, doi: 10.1016/j.intimp.2025.114605.
[22] A. Dirican et al., “EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB ON EXPERIMENTAL RENAL CELL CANCER MODELS,” Sağlık Bilimlerinde İleri Araştırmalar Dergisi / Journal of Advanced Research in Health Sciences, 2022, doi: 10.26650/jarhs2021-1133817.
[23] A. M. Kabel, M. A. E. Rashidy, and M. S. Omar, “Ameliorative potential of tamoxifen/thymoquinone combination in patients with breast cancer: A biochemical and immunohistochemical study,” Journal of Cancer Science and Research, 2018, doi: 10.4172/2576-1447.1000102.
[24] G. Nabil, F. Zahran, A. N. Elmeshad, A. Fawzy, D. M. Ghalwash, and B. Elsaadany, “Evaluation of thymoquinone cancer chemo-preventive effect on oral leukoplakia: A randomized clinical trial,” Exploration of Medicine, 2025, doi: 10.37349/emed.2025.1001290.
[25] F. Elbarbry, A. Ung, and K. Abdelkawy, “Studying the inhibitory effect of quercetin and thymoquinone on human cytochrome P450 enzyme activities,” Pharmacognosy Magazine, 2018, doi: 10.4103/0973-1296.224342.
[26] A. Megawati, A. E. Nugroho, E. Lukitaningsih, D. A. Prihati, and A. Nurrochmad, “Thymoquinone increased warfarin 7-hydroxylation in human liver microsomes and induced the expression of CYP2C9 in HepG2 cells,” Indonesian Journal Of Pharmacy, 2024, doi: 10.22146/ijp.10966.
[27] S. P. Eftekhar, S. Kazemi, and A. A. Moghadamnia, “Effect of thymoquinone on pharmacokinetics of 5-fluorouracil in rats and its effect on human cell line in vitro,” Human & experimental toxicology, 2022, doi: 10.1177/09603271221145422.
[28] M. G. Alrashedi, A. S. Ali, S. S. Ali, and L. M. Khan, “Impact of thymoquinone on cyclosporine a pharmacokinetics and toxicity in rodents,” The Journal of pharmacy and pharmacology, 2018, doi: 10.1111/jphp.12943.
[29] K. M. Alkharfy, B. L. Jan, M. Raish, N. Haq, and A. Ahmad, “A sensitive rapid and environmentally friendly UHPLC assay method for the determination of thymoquinone in plasma samples and its analytical application,” Journal of Chromatographic Science, 2020, doi: 10.1093/chromsci/bmaa027.
[30] E. Khaikin, S. Chrubasik-Hausmann, S. Kaya, and B. F. Zimmermann, “Screening of thymoquinone content in commercial nigella sativa products to identify a promising and safe study medication,” Nutrients, 2022, doi: 10.3390/nu14173501.
[31] C. Rathore et al., “Enhanced oral bioavailability and hepatoprotective activity of thymoquinone in the form of phospholipidic nano-constructs,” Expert opinion on drug delivery, 2020, doi: 10.1080/17425247.2020.1716728.
[32] F. Odeh, S. I. Ismail, R. Abu-Dahab, I. S. Mahmoud, and A. A. Bawab, “Thymoquinone in liposomes: A study of loading efficiency and biological activity towards breast cancer,” Drug Delivery, 2012, doi: 10.3109/10717544.2012.727500.
[33] M. A. Khan, M. Azam, and H. Younus, “In silico and in vitro studies to explore the effect of thymoquinone on isocitrate lyase, biofilm formation, and the expression of some virulence genes in candida albicans,” Current Issues in Molecular Biology, 2024, doi: 10.3390/cimb46110771.
[34] Ö. Ö. Zincir et al., “Synergistic effect of thymoquinone and nystatin in the treatment of oral candidiasis; an in vitro study,” Odontology, 2022, doi: 10.1007/s10266-021-00667-4.
[35] N. Nouri et al., “Thymoquinone antifungal activity against candida glabrata oral isolates from patients in intensive care units—an in vitro study,” Metabolites, 2023, doi: 10.3390/metabo13040580.